Skip to Main Content

Clinical Trial to Evaluate the Efficacy, Safety, and Tolerability of BMS-986089 in Ambulatory Boys With Duchenne Muscular Dystrophy

Conditions

Diseases of the Musculoskeletal System | Genetics - Pediatric

Phase II-III

What is the purpose of this trial?

This is a multi-center, randomized, double-blind, placebo-controlled study to assess the efficacy, safety and tolerability of two different weekly doses of BMS-986089 in ambulatory boys with Duchenne Muscular Dystrophy (DMD).

  • Trial with
    Bristol-Myers Squibb Research and Development
  • Start Date
    05/30/2018
  • End Date
    07/29/2020
Trial Image

For more information about this study, contact:

Novagrami George

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    06/05/2018
  • Study HIC
    #2000021057